ES2894836T3 - Compuestos de CBD fluorados, composiciones y usos de los mismos - Google Patents
Compuestos de CBD fluorados, composiciones y usos de los mismos Download PDFInfo
- Publication number
- ES2894836T3 ES2894836T3 ES14709750T ES14709750T ES2894836T3 ES 2894836 T3 ES2894836 T3 ES 2894836T3 ES 14709750 T ES14709750 T ES 14709750T ES 14709750 T ES14709750 T ES 14709750T ES 2894836 T3 ES2894836 T3 ES 2894836T3
- Authority
- ES
- Spain
- Prior art keywords
- disease
- compound
- branched
- straight
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(CC1*)C(*)C(*)C1c1c(*)c(*)c(*)c(*)c1* Chemical compound CC(CC1*)C(*)C(*)C1c1c(*)c(*)c(*)c(*)c1* 0.000 description 1
- HWORBCMIBDAHCA-UHFFFAOYSA-N CC(CCC1C(N)=C)=CC1c(c(O)cc(N)c1)c1O Chemical compound CC(CCC1C(N)=C)=CC1c(c(O)cc(N)c1)c1O HWORBCMIBDAHCA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/373—Halogenated derivatives with all hydroxy groups on non-condensed rings and with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/42—Halogenated derivatives containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/16—Acetic acid esters of dihydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/63—Halogen-containing esters of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750043P | 2013-01-08 | 2013-01-08 | |
| PCT/IL2014/050023 WO2014108899A1 (en) | 2013-01-08 | 2014-01-08 | Fluorinated cbd compounds, compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2894836T3 true ES2894836T3 (es) | 2022-02-16 |
Family
ID=50272668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14709750T Active ES2894836T3 (es) | 2013-01-08 | 2014-01-08 | Compuestos de CBD fluorados, composiciones y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US9447019B2 (enExample) |
| EP (1) | EP2943463B1 (enExample) |
| JP (3) | JP6228230B2 (enExample) |
| CN (1) | CN105209424B (enExample) |
| AU (2) | AU2014206036B2 (enExample) |
| CA (1) | CA2935899C (enExample) |
| ES (1) | ES2894836T3 (enExample) |
| MX (1) | MX381719B (enExample) |
| WO (1) | WO2014108899A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014206036B2 (en) | 2013-01-08 | 2017-11-02 | Universidade De Sao Paulo - Usp | Fluorinated CBD compounds, compositions and uses thereof |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| AU2016293387A1 (en) * | 2015-07-16 | 2018-01-25 | Universidade De São Paulo - Usp | Flourinated CBD compounds, compositions and uses thereof |
| US11207414B2 (en) | 2015-09-22 | 2021-12-28 | Graphium Biosciences, Inc. | Cannabinoid glycoside prodrugs and methods of synthesis |
| MX2018004632A (es) * | 2015-10-16 | 2018-11-09 | Scythian Biosciences Inc | Metodos y composiciones para el tratamiento de una lesion cerebral traumatica. |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| EP3634390B1 (en) | 2017-05-09 | 2023-09-27 | Graphium Biosciences, Inc. | Antimicrobial compositions comprising cbd or thc against c. difficile infection or e. faecalis |
| CA3065167A1 (en) * | 2017-05-31 | 2018-12-06 | Phytecs, Inc. | Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use |
| CA3300266A1 (en) | 2017-09-28 | 2026-03-02 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
| IL325123A (en) | 2018-12-14 | 2026-02-01 | Harmony Biosciences Man Inc | Treating 22q11.2 Deficiency Syndrome with Cannabidiol |
| EP4069215B1 (en) | 2019-12-06 | 2026-07-01 | Jlabs Beauty LLC | Topical compositions containing rose oil and cannabidiol, and processes for their preparation and use |
| CA3173339A1 (en) | 2020-02-26 | 2021-09-02 | Graphium Biosciences, Inc. | Novel cannabinoid glycosides and uses thereof |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| EP4153306A4 (en) | 2020-05-22 | 2024-06-26 | Ilera Derm LLC | Compositions for treating acne and dermatological conditions |
| GB202009321D0 (en) | 2020-06-18 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2642523A (en) * | 2024-07-12 | 2026-01-14 | Sonas Pharmaceuticals N I Ltd | Novel halogenated cannabinoid derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
| DK2176208T3 (en) * | 2007-07-30 | 2015-04-27 | Zynerba Pharmaceuticals Inc | Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof |
| WO2011006099A1 (en) * | 2009-07-10 | 2011-01-13 | Northeastern University | Angiogenic resorcinol derivatives |
| PT2473475T (pt) * | 2009-08-31 | 2017-08-02 | Zynerba Pharmaceuticals Inc | Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas |
| WO2012011112A1 (en) * | 2010-07-22 | 2012-01-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Non psychoactive cannabinoids and uses thereof |
| AU2014206036B2 (en) | 2013-01-08 | 2017-11-02 | Universidade De Sao Paulo - Usp | Fluorinated CBD compounds, compositions and uses thereof |
-
2014
- 2014-01-08 AU AU2014206036A patent/AU2014206036B2/en active Active
- 2014-01-08 EP EP14709750.5A patent/EP2943463B1/en active Active
- 2014-01-08 US US14/759,689 patent/US9447019B2/en active Active
- 2014-01-08 WO PCT/IL2014/050023 patent/WO2014108899A1/en not_active Ceased
- 2014-01-08 CN CN201480012168.2A patent/CN105209424B/zh active Active
- 2014-01-08 JP JP2015551255A patent/JP6228230B2/ja active Active
- 2014-01-08 ES ES14709750T patent/ES2894836T3/es active Active
- 2014-01-08 MX MX2015008766A patent/MX381719B/es unknown
- 2014-01-08 CA CA2935899A patent/CA2935899C/en active Active
-
2016
- 2016-08-19 US US15/241,557 patent/US9782360B2/en active Active
-
2017
- 2017-08-01 US US15/666,128 patent/US10441553B2/en active Active
- 2017-10-12 JP JP2017198146A patent/JP2018065794A/ja active Pending
-
2018
- 2018-01-24 AU AU2018200570A patent/AU2018200570B2/en active Active
-
2019
- 2019-01-28 JP JP2019012349A patent/JP6952727B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014108899A1 (en) | 2014-07-17 |
| US20150344403A1 (en) | 2015-12-03 |
| CA2935899A1 (en) | 2014-07-17 |
| AU2018200570B2 (en) | 2019-09-26 |
| AU2014206036A2 (en) | 2016-06-16 |
| AU2014206036A1 (en) | 2015-08-13 |
| CA2935899C (en) | 2021-08-31 |
| CN105209424B (zh) | 2019-12-13 |
| US20170326078A1 (en) | 2017-11-16 |
| JP6952727B2 (ja) | 2021-10-20 |
| EP2943463B1 (en) | 2021-07-14 |
| EP2943463A1 (en) | 2015-11-18 |
| MX2015008766A (es) | 2016-03-07 |
| HK1214586A1 (zh) | 2016-07-29 |
| JP2016505614A (ja) | 2016-02-25 |
| US20170197904A1 (en) | 2017-07-13 |
| JP6228230B2 (ja) | 2017-11-08 |
| US9782360B2 (en) | 2017-10-10 |
| US10441553B2 (en) | 2019-10-15 |
| US9447019B2 (en) | 2016-09-20 |
| JP2018065794A (ja) | 2018-04-26 |
| AU2014206036B2 (en) | 2017-11-02 |
| AU2018200570A1 (en) | 2018-02-15 |
| CN105209424A (zh) | 2015-12-30 |
| MX381719B (es) | 2025-03-12 |
| JP2019073547A (ja) | 2019-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018200570B2 (en) | Fluorinated cbd compounds, compositions and uses thereof | |
| ES3053660T3 (en) | Pharmaceutical combination comprising ponesimod and its use in the treatment of multiple sclerosis | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| ES2736507T3 (es) | 2-Tioxo-imidazolidin-4-onas sustituidas y análogos espiro de las mismas, ingrediente activo contra el cáncer, composición farmacéutica, preparación medicinal, método para tratar cáncer de próstata | |
| CN106478502B (zh) | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 | |
| US20190084909A1 (en) | Fluorinated cbd compounds, compositions and uses thereof | |
| CN107021961B (zh) | 一类具有辐射防护作用的新化合物、其制备方法及其药物应用 | |
| KR102784814B1 (ko) | 항불안제 제조시 치환된 신남아미드 유도체의 적용 | |
| CN102584683B (zh) | Tempol类衍生物的合成及辐射防护作用 | |
| KR101855087B1 (ko) | 칼콘 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 미토콘드리아의 산소 소모율 감소에 의해 야기되는 질환의 예방 또는 치료용 약학 조성물 | |
| JP2009538822A (ja) | 静脈におけるウイルスの治療 | |
| JP2009538822A5 (enExample) | ||
| ES2808667T3 (es) | Derivados de diarilmetilideno piperidina y su uso como agonistas del receptor opioide delta | |
| BR112015016492B1 (pt) | Compostos cbd fluorados, composições e usos | |
| US20250161241A1 (en) | Cysteamides, therapeutic compositions thereof, and related methods | |
| US11370743B2 (en) | Prodrug derivatives of protein kinase C modulators | |
| CA3005120A1 (en) | New molecules from seaweeds with anti-cancer activity | |
| TW201513849A (zh) | 藉由合成之帕那司托（ｐａｎａｘｙｔｒｉｏｌ）類似物之毒性下降 | |
| CN105395531A (zh) | 8-甲基-n-香草基-反-6-壬烯酰胺在制备治疗肝癌药物中的用途 | |
| CN102603614B (zh) | 4-甲氧甲基-4-(n-取代)苯胺哌啶类化合物、制备方法及用途 | |
| WO2024002112A1 (zh) | 一种治疗猫冠状或杯状病毒感染的方法 |